Cautionary statement regarding forward-looking statements

This presentation may contain forward-looking statements. Forward-looking statements give the Group’s current expectations or forecasts of future events. An investor can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as ‘anticipate’, ‘estimate’, ‘expect’, ‘intend’, ‘will’, ‘project’, ‘plan’, ‘believe’, ‘target’ and other words and terms of similar meaning in connection with any discussion of future operating or financial performance. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, dividend payments and financial results.

Other than in accordance with its legal or regulatory obligations (including under the Market Abuse Regulations, UK Listing Rules and the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority), the Group undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. Investors should, however, consult any additional disclosures that the Group may make in any documents which it publishes and/or files with the US Securities and Exchange Commission (SEC). All investors, wherever located, should take note of these disclosures. Accordingly, no assurance can be given that any particular expectation will be met and investors are cautioned not to place undue reliance on the forward-looking statements.

Forward-looking statements are subject to assumptions, inherent risks and uncertainties, many of which relate to factors that are beyond the Group’s control or precise estimate. The Group cautions investors that a number of important factors, including those in this presentation, could cause actual results to differ materially from those expressed or implied in any forward-looking statement. Such factors include, but are not limited to, those discussed under Item 3.D ‘Risk factors’ in the Group’s Annual Report on Form 20-F for FY 2020 and any impacts of the COVID-19 pandemic. Any forward-looking statements made by or on behalf of the Group speak only as of the date they are made and are based upon the knowledge and information available to the Directors on the date of this presentation.

A number of adjusted measures are used to report the performance of our business, which are non-IFRS measures. These measures are defined and reconciliations to the nearest IFRS measure are available in our first quarter 2021 earnings release and Annual Report on Form 20-F for FY 2020.

All expectations and targets regarding future performance and the dividend should be read together with the section “Outlook, assumptions and cautionary statements” on pages 42 and 43 of our first quarter 2021 earnings release.
Creating significant long-term shareholder value with two new companies

2017

- **Innovation**
- **Performance**
- **Trust**

2022

- **New GSK**
  - Update June 23 2021
- **New Consumer Healthcare**
  - CMD H1 2022

☑️ Invest in R&D pipeline and improve productivity
☑️ Sharpen commercial execution, refocus portfolio, drive cost discipline
☑️ Address group structure and capital allocation
☑️ Drive culture of ambition and accountability while maintaining leadership in ESG
Focused ESG approach to support delivery of long-term sustainable performance

- Pricing/Access
- Environment
- Global Health & Health security
- Product governance
- Inclusion & Diversity
- Operating standards
### ESG areas of focus: Pricing and access

<table>
<thead>
<tr>
<th>Pricing/Access</th>
<th>Environment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Global Health &amp; Health security</td>
<td>Product governance</td>
</tr>
<tr>
<td>Inclusion &amp; Diversity</td>
<td>Operating standards</td>
</tr>
</tbody>
</table>
## ESG areas of focus: Global health and Health security

<table>
<thead>
<tr>
<th>Pricing/Access</th>
<th>Environment</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Global Health &amp; Health security</strong></td>
<td><strong>Product governance</strong></td>
</tr>
<tr>
<td>Inclusion &amp; Diversity</td>
<td><strong>Operating standards</strong></td>
</tr>
</tbody>
</table>
ESG areas of focus: Inclusion and Diversity

<table>
<thead>
<tr>
<th>Pricing/Access</th>
<th>Environment</th>
<th>Commitments to accelerate progress on I&amp;D by 2025</th>
</tr>
</thead>
<tbody>
<tr>
<td>Global Health &amp; Health security</td>
<td>Product governance</td>
<td><strong>Gender</strong> Increase female leaders (VP and above) to 45% globally</td>
</tr>
<tr>
<td>Inclusion &amp; Diversity</td>
<td>Operating standards</td>
<td><strong>Ethnicity</strong> Increase ethnically-diverse leaders (VP and above) to at least 30% in the US and 18% in the UK</td>
</tr>
</tbody>
</table>
ESG areas of focus: Environment

<table>
<thead>
<tr>
<th>Pricing/Access</th>
<th>Environment</th>
<th>Ambitious environmental targets</th>
</tr>
</thead>
<tbody>
<tr>
<td>Global Health/ health security</td>
<td>Product governance</td>
<td>Climate action: Net zero impact on climate by 2030</td>
</tr>
<tr>
<td>Inclusion &amp; Diversity</td>
<td>Operating standards</td>
<td>Nature action: Positive impact on nature by 2030</td>
</tr>
</tbody>
</table>

The LEAF Coalition
Lowering Emissions by Accelerating Forest Finance
ESG areas of focus: Product Governance and Operating standards

<table>
<thead>
<tr>
<th>Pricing/Access</th>
<th>Environment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Global Health/ health security</td>
<td>Product governance</td>
</tr>
<tr>
<td>Inclusion &amp; Diversity</td>
<td>Operating standards</td>
</tr>
</tbody>
</table>
Integrating ESG into operations to ensure delivery

- Integrated across operations and incentivised
- Benchmarked with visible public commitments
- Part of capital allocation approach
ESG leader in key ratings and indices

Access to Medicine Index
1st

Dow Jones Sustainability Index
2nd in the Pharma sector

MSCI
AA

Sustainalytics
21.3 ESG risk rating

CDP
A in water, B in Carbon, Leader for Supplier Engagement

Science Based Targets
Accredited for 1.5°C aligned emissions targets (scopes 1,2 and 3)

Vigeo Eiris
1st in the Pharma sector

Antimicrobial Resistance benchmark
Lead pharma company

1.5°C Lead pharma company
ESG performance to deliver health impact and shareholder returns

- Sustainable performance and long-term growth
- Trust for all stakeholders
- Reduced risk to operations
- Positive social impact

New GSK to positively impact the health of >2.5 bn people over 10 years